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Abstract 
Patient reported outcome measures (PROMs) are a useful way of recording patient 
perceptions of the impact of their cancer and the consequences of treatment.  
Understanding the impact of radiotherapy longer term requires tools that are sensitive to 
change but also meaningful for patients. PROMs are useful in defining symptom severity but 
also the burden of illness for cancer patients. Patient reported outcomes are increasingly 
being seen as a way to improve practice by enhancing communication, improving symptom 
management as well as identifying patient care needs. This paper provides an overview of 
the use of PROMs in radiotherapy and considerations for tool choice, analysis and the 
logistics of routine data collection. Consistent assessment is essential to detect patient 
problems as a result of radiotherapy but also to address emerging symptoms promptly. 
 
Introduction 
 
The number of cancer survivors is increasing as earlier detection and better therapies have 
brought about significant advances in survival rates. In Europe 46% of all those diagnosed 
with cancer will be living 10 or more years beyond initial treatment (1).  By 2030 it is 
projected that there will be more than 4 million cancer survivors within the UK population (2) 
and 13.7 million in the USA (3). Monitoring the health of survivors is crucial in comparing 
long-term outcomes from cancer therapies (4) (5). Recording the impact of different 
treatments on individuals quality of life and health burden is an important part of patient 
reported outcomes (6),(7).  
 
Systematic monitoring of late effects from radiotherapy is important in determining normal 
tissue effects and measuring dose response (8). However, consistent assessment is rarely 
undertaken routinely in the UK. It is however essential to detect patient problems as a result 
of therapy but also to address emerging symptoms promptly and meet patients healthcare 
needs (9, 10). Consideration beyond treatment efficacy particularly with determining 
potential risk of long term side-effects is required for informing clinician and patient decision 
making, especially when differences in survival maybe small between therapies (11).  
 
Self-rated health measures have been found to be a powerful predictor of morbidity and 
mortality compared to many objective measures of health (Chase et al 2012) so show 
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evidence of substantial benefit for clinical practice (12). Patient reported measures have 
been shown to have equivalence to physician reported measures in radiotherapy (13, 14). 
Developing prospective and long-term methods for future patient assessment requires 
measurement of patients’ perceptions of their symptoms and recording of health outcomes 
over a considerable period of time. 
 
Patient reported outcomes (PRO) are currently a force for clinical improvement driven not 
only by health policy initiatives but also to improve patient centred health (15), (16).  Patient 
reported outcome measures (PROMS) are “standardised, validated questionnaires that are 
completed by patients to measure their perceptions of their own functional status and 
wellbeing” (17). PROMS are increasingly being used to make comparisons of health 
outcomes across healthcare settings (18, 19).  
 
This paper explores the benefits and challenges of PROMS for use in radiotherapy practice. 
We consider the conceptual differences between tools together with the most useful way of 
capturing, analysing PROMs and utilising the data. Finally we provide guidance for 
radiotherapy clinicians keen to use patient reported outcome measures in radiotherapy 
research and practice. 
 
What are the differences between patient reported outcome measures? 
 
There has been a proliferation of PROMS over the last few years and many are used within 
oncology. PROMS can range from multi-dimensional measures of patient’s global 
perceptions of their health to specific tools that assess severity of symptoms (16, 20). It is 
important to distinguish between types of PROMs as they measure conceptually different 
items (Figure 1).  
 
Generic PROMs, such as Health Related Quality of Life (EQ-5D), measure the patient’s 
perceptions and societal values of the impact of disease and treatment. These generic tools 
measure health as the ability to function, often emotionally, physically and socially but can 
be strongly influenced by environmental factors (20). They provide population based data 
that is useful for comparison, provides data for health economics but have low sensitivity to 
change at an individual level. Disease specific PROMs ask patients about condition specific 
problems such as quality of life (EORTC-QOL C30) with disease specific attributes and even 
more specific symptom scores such as anxiety and depression and body image scale 
(HADs, BIS). These condition specific measures have high patient relevance and sensitivity 
but provide poorer population relevant data (19). Such symptom focused PROMs are best at 
recording severity but are prone to response shift over time for example patients adapt to 
health changes and therefore the impact on patient reported outcome reduces over time 
(21). This can be seen in Mukesh et al (22) study where PROMs reporting breast changes 
after radiotherapy were under reported over time compared to clinician assessments. 
 
PROMS do not ask about patient experience of care, opinions or satisfaction with health 
care: these are not health outcomes (15). PROMS can provide descriptive richness and 
detail, they fall across a continuum of sensitivity to generalizability and the choice of 
measurement instrument therefore depends on the target coverage of content, sensitivity of 
that target to change and the potential for comparison. Combining measures to target 
different aspects of patient reported outcomes is an approach that enables relationships to 
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be explored between more global and specific impact and may be especially informative in 
intervention evaluation (19). To understand change PROMs must be used across time, such 
as before and after radiotherapy so that it is possible to gauge what improvement or 
deterioration has occurred and patient needs. 
 
 
Evidence of benefits of PROMs for improving clinical practice 
 
Increasingly patient follow-up after radiotherapy is changing with workflow alterations for 
clinical oncologists reducing patient contact for those after treatment and greater use of 
remote and telephone follow up and discharge to primary care (23). The ability to assess 
patients remotely and provide systematic assessment of radiotherapy late effects is reliant 
now on PROMs. The benefits of PROMs as part of clinical review have been observed in a 
range of studies. However in a meta-analysis of PROMs effect on outcomes and processes 
of care they were seen to increase detection of patient problems, enhance symptom control 
and improve supportive care measures (12).  Communication was not enhanced in this 
meta-analysis despite indications from single studies (24). The effect size of such changes 
was small and the psychometric robustness of some of the PROM tools questioned by 
authors in their ability to evaluate the intervention required. Although routine collection of 
PROMS are perceived positively the need for automated systems to identify any areas that 
require specific attention is required to support clinician decision making (25). The logistics 
of collecting PROs in clinical practice is challenging and are dependent on the resources 
available. Useful methodological and logistical tips for successful integration of PROMS into 
routine clinical practice are provided (15, 26). Research is on-going in evaluating such 
approaches in oncology (27). PROMs are useful to facilitate open discussions, and also to 
identify areas of concern during treatment follow-ups.   
 
How are PROMs used in radiotherapy research?  
 
PROMs have widespread use in pharmaceutical intervention studies with detailed guidance 
in their inclusion to support efficacy claims and approval of new drugs. The FDA revised 
guidance in 2009 raised the stakes for the use of PROMs in clinical research resulting in a 
major shift in how PROM assessments were viewed (28). Fundamental to this was bringing 
the patient perspectives into developing PRO instruments emphasising the content validity 
and requiring that PRO instruments adequately measure what is claimed, that is they are 
psychometrically tested for that population and that the PRO endpoint is clear in the clinical 
trial.  In the past such requirements for inclusion of PROs in radiotherapy research were not 
required however much can be learnt from standards of PRO use in identifying tool validity 
within radiotherapy (29) (20). Subsequently the field of PROM development is rapidly 
changing with tools being revised and developed constantly. 
 
This element of change creates difficulties in comparing old with new PROMs. However this 
is less of a problem as item analysis and detail of analysis in reporting can address 
comparisons for future studies. More critically the small incidence of severe late effects and 
lack of specificity to radiotherapy effects mean that PROM tools rarely have precision in 
detecting significant differences between radiotherapy treatments. The evolving basis of 
treatment and emerging late effects for cancer survivors requires researchers to look ahead 
so that emerging treatment effects can be captured in relation the HRQOL(30). This means 
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there is a need for PRO measures across the spectrum (Figure 1) to be able to predict future 
requirements and analyse treatment effects. 
 
Graff in 2002 (31) reviewed PRO measures used in radiotherapy between 1990 and 2001. 
The tools most frequently used were EORTC QLQ-C30 and the FACT G with corresponding 
tumour modules. We have conducted a similar analysis of studies. Table 1 gives a sample of 
PROM instruments used in clinical trials, which involve radiotherapy, and were either 
primarily conducted in the UK or participated by UK centres. Although this is not an 
exhaustive list, it shows that the questionnaires developed by the EORTC’s Quality of Life 
group are widely used, including the core, generic tool (QLQ-C30) as well as cancer specific 
modules. Most studies used a combination of generic and specific questionnaires, both 
within the EORTC tools (e.g. EORTC QLQ-C30 combined with BN20 for brain cancer) and 
beyond (e.g. SF-36, a generic tool combined with prostate-specific UCLA-PCI for prostate 
cancer), though this is not always the case. It is worth noting that when multiple tools are 
used together, they may contain overlapping questions, differences in scaling and these may 
result in differences in PRO results within the same study (32). Our results were similar to 
Graff in that it is important to know what you intend to measure, why you want to measure it 
and be sure the PRO instrument you choose measures what is intended or use tools that 
include both global and specific PROM concepts. 
 
PROMS, data analysis the challenge of incomplete data 
 
The general challenges that affect PROMs, just as with any other type of data, include 
dealing with missing data, the abundance of information generated from PROMs collected 
over time and the need to summarise or transform scores to reverse questions that may 
have different polarity i.e. negative to positive. This may require variable selection prior to 
further analysis and requires a clear PROM analysis plan from the beginning of the research. 
Most PROM tools provide guidance on analysis. In addition, depending on the study 
research question, stratification of patients may require attention when analysing PROM 
data. For example in large multicentre studies the information on hospital, deprivation or 
cancer stage (risk group) may need to be included. In this type of analysis patients are 
stratified within their groups. Groupings between patients may significantly affect the 
outcome of the study (and mask the main effect) and therefore it is important to take it into 
account to enable detection of the main effect and to comprehensively answer the 
experimental question.  
Missing data cannot be completely prevented, due to various reasons. Often patients do not 
provide all the answers to the questions, and there may be specific questions that patients 
may not understand, prefer not to answer or may consider to be irrelevant. Alternatively, it is 
possible that clinicians may fail to give out or collect forms. Respective of which data are 
missing, missing data can be divided into two types; drop-outs and intermittent (33). 
Dropouts are when participants fail to deliver the whole assessment on a specified occasion 
(for example did not attend) and this is especially typical for longitudinal studies when some 
of the participants may be lost to follow-up.  
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One of the most commonly applied methods of dealing with missing data in PROMs is 
complete case analysis. It is a traditional approach that is currently not recommended in the 
methodological literature (34). This approach clears the data from that missing by removing 
incomplete cases, and this enables the statistical software to process the data. However, it 
can have some serious disadvantages in introducing bias. Some analytical approaches, 
such as those that use correlation coefficient, allow for pairwise deletion of missing 
variables. This preserves some data but has implications when interpreting the results 
because each measurement is based on a different number of samples. However, for most 
of the multivariate approaches e.g. regression, the whole assessment has to be deleted (list-
wise deletion) if it contains at least one unanswered question (35). Subsequently, there is a 
risk that conclusions may be biased towards patients with complete assessments, and 
secondly the loss of power of the analysis that is associated with the sample number may be 
significant. The assumption that the complete cases are random selections of samples and 
that they will provide adequate representation of the entire dataset is very rarely supported 
(36). Alternative methods are available and recommended for use in PROMs. They involve 
various way of imputing missing data. Traditionally, missing data in PROMs was imputed 
with the rounded mean or median of the variable, or in the case of dropouts by the last 
observation that is carried forward. However, more advanced imputation algorithms are 
currently being developed and used more in PROMs analysis (ref). They utilize maximum 
likelihood estimation and various multiple imputation algorithms. The choice of the 
imputation approach depends on the type of data, and has to be carefully considered taking 
into account mechanisms of missing data as defined by Ruben (34). Multiple imputation has 
been shown to be beneficial in addressing missing data in PROMs and is now the 
recommended approach for dealing with missing data in PROMs (37). 
 
Other challenges that are more PROM specific involve including the mixture of variables that 
are measured on different scales. Binary, categorical, ordinal and Likert scales are 
commonly used in PROMs. Comparing the relationship, content and scaling between 
PROMs is essential (20). Data preparation and statistical approaches are required that are 
appropriate for this type of variables and allow for analysis with variables on mixture of 
scales. Analysis of PROMs where there are repeated measurements over time creates yet 
another challenge and this has been raising much interest in the area of analysis of PROMs. 
Investigating trends in time and utilising the information on change in PROMs e.g. from the 
baseline or during or after treatment (38). 
 
The preparation of PROMs data and choice of analytical techniques has to be carefully 
tailored to the scales of variables. Choosing between parametric and non-parametric 
statistics is particularly crucial. In a PROMs dataset when those questions are collected from 
a large number of participants, the variables (especially those within one domain) exhibit a 
high degree of collinearity that may pose a challenge for the analysis. Therefore, for the 
purpose of meaningful data analysis, pre-processing may require some degree of data 
reduction and/or variable selection. In some studies, the research question underpins 
justification for picking some symptoms and leaving others out for the PROM analysis. 
However, approaches that do not use any systematic variable selection will generally be 
criticised. For variable reduction some instrument specific scoring instructions suggest 
calculating average values for the items that belong to the same domain. However, this 
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indiscriminate approach can lead to a loss of important information. This is because not all 
the symptoms in the same domain are always highly correlated and thus can be condensed 
into one aggregate measure. To overcome this we recently proposed an approach that uses 
symptom clustering for variable reduction and selection. It was shown that clusters do not 
necessarily follow the domain pattern. We therefore recommend that average values, based 
on symptom clusters rather than domains, should be used (38).   
 
Appraisal of the effect size and target of PROM instruments in radiotherapy 
 
The main purpose of collecting PROMs is to improve patients’ health related outcomes and 
increasingly in cancer survival studies focus is on the long term outcomes (39). Clinical utility 
of PROMS depends on the availability of information about clinical severity thresholds and 
what is important for a clinically meaningful change score for the patient (19). Kotronoulas 
and colleagues (12) found that effect sizes were small when evaluating PROM studies n 
cancer as interventions for improving outcomes and that the number of statistical findings 
within the evidence base is small. Two broad approaches to defining clinical effectiveness 
are recommended these include the use of distribution score information and the use of 
patient population rated “anchors” by which to estimate meaningful difference (19). A 
PROMS track record offers a practical indication of its psychometric properties so reviewing 
similar studies or patient populations can be a good way to choose a PROM. Widespread 
use does not mean that the tool has superior benefits but it is an advantage to compare 
across studies.  
 
Conclusion 
In conclusion can PROMs replace objective measures in radiotherapy? The answer is 
clearly yes but these tools require skill to use. The field of PRO measurement is a dynamic 
one and is moving fast, measures are becoming obsolete and new ones such as the US 
PROMIS generated by computer adaptive testing. Changes to workflow and increasing 
volume of patients mean that PROMS are a way to overcome shortcomings in toxicity 
reporting and can help clinical oncologists identify what is important for patients when they 
return to clinic and improve symptom management and communication. Including PROMs in 
routine practice will become more commonplace but research is needed to be able to best 
develop tools and content validity that is suitable for radiotherapy. 
PROMs in research are well utilised but the quality of reporting is still poor in that large 
amounts of data is captured but not necessarily utilised in the final analysis. Developing the 
PRO research question and using the breadth of PROM concepts is essential to improve 
targeting of outcomes and generalizability of research. In the review of current studies few 
used symptom specific tools or patient generate index (PGI), which can mean that the 
condition specific tools may lack content validity for radiotherapy effects or individual 
problems that emerge as new treatments are developed. We need to consider the focus of 
the research question for survivorship research and the sensitivity of the PROM to be able to 
demonstrate change. There are limitations to PROMs in that the logistics of capture are time 
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consuming and require administrative skill, however new technologies are making this 
increasingly possible. 
With the small number of radiation events future data pooling of PROMs and the ability to 
share between studies through data linkage promises exciting opportunities to study larger 
treatment effects and risk prediction. Do we need new PROM tools for radiotherapy or does 
it need to be driven by HRQOL groups and patients.  PROMS are important for 
understanding patients experience and perceptions and therefore any new tools need to be 
embedded and follow the psychometric methodologies currently endorsed by the FDA. 
Patient generated tools are likely to be the future but as yet are not wide spread because of 
the technology requirements. 
PROMS are an opportunity for clinical oncology because they offer the ability to assess 
patients’ and collect long-term data often remotely. Changes in cancer care pathways means 
that patients receiving radiotherapy are less likely to be seen long term by their clinical 
oncologist (40) as changes in workflow and patient survivorship increase this means that 
follow up is less likely to be at the cancer centres. PROs provide benefits in demand 
management and can enhance services by providing innovation in co-ordinated process for 
surveillance, help patients make decisions and provide valuable observational data of 
population effects and differences in therapies that would not be seen in clinical trials. 
 
 
 
Figure 1. Continuum from specificity to generalizability and the relationship of common 
cancer PROMs: the use of a range of tools provides a wider picture of patient impact. 
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Table 1: A sample of PROM instruments used in UK radiotherapy clinical trials from 2005-
2014. 
Cancer site Trial  PROM instrument Reference 
Bladder BC2001 EORTC QLQ-C30 (41) 
Brain AVAGLIO EORTC QLQ-C30, 
EORTC QLQ-BN20 
(42) 
Breast START EORTC QLQ-C30,  
EORTC QLQ-BR23,  
BIS, 
HADS 
(43) 
Head & neck PARSPORT EORTC QLQ-C30,  
EORTC QLQ-H&N35, 
Modified xerostomia 
questionnaire 
(44) 
Lung SOCCAR EORTC QLQ-C30,  
Euro-QoL EQ-5D 
(45) 
Prostate RT01, 
CHHiP 
SF-36,  
UCLA-PCI,  
FACT-P 
(46) (47) 
Rectum CR07 SF-36, 
EORTC QLQ-CR38 
(48) 
Testicle TE18 EORTC QLQ-C30, 
EORTC QLQ-TC26 
(49) 
 
Abbreviations: BIS: Body Image Scale; EORTC QLQ: European Organisation for the 
Research and Treatment Quality of Life Questionnaire, including C30 (Core 30), BN20 
(Brain Cancer Module), BR23 (Breast Cancer Module), H&N35 (Head and Neck Module), 
CR38 (Colorectal Cancer Module), TC26 (Testicular Cancer Module); EQ-5D: Euro-QoL-5 
Dimension; FACT-P: Functional Assessment of Cancer Therapy – Prostate; HADS: Hospital 
Anxiety and Depression Scale; SF-36: Short Form 36; UCLA-PCI: University of California 
Los Angeles Prostate Cancer Index. 
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